+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

New oral anticoagulants in the treatment of venous thromboembolic disease



New oral anticoagulants in the treatment of venous thromboembolic disease



Semergen 39(3): 146-149



Rivaroxaban is a direct inhibitor of activated factor X, and dabigatran is a direct inhibitor of thrombin. These new oral anticoagulants have demonstrated to be effective and safe in clinical trials on the treatment of venous thromboembolic disease (deep vein thrombosis and pulmonary thromboembolism).

(PDF emailed within 0-6 h: $19.90)

Accession: 054611230

Download citation: RISBibTeXText

PMID: 23540987

DOI: 10.1016/j.semerg.2012.10.007


Related references

Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease. Annals of Vascular Surgery 42: 337-350, 2017

Extended anticoagulant treatment of venous thromboembolic disease with direct oral anticoagulants. Semergen 44(7): 500-503, 2018

A Cost-Effectiveness Analysis Of Novel Oral Anticoagulants For Acute Treatment And Secondary Prevention Of Venous Thromboembolic Disease. Value in Health 18(7): A390-A390, 2015

Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opinion on PharmacoTherapy 17(15): 2033-2047, 2016

The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED. American Journal of Emergency Medicine 32(12): 1526-1533, 2015

Results of administering oral anticoagulants for treatment of patients with venous thromboembolic complications. Angiologiia i Sosudistaia Khirurgiia 23(2): 82-87, 2017

A Cost-Effectiveness Analysis of Novel Oral Anticoagulants for Primary Prevention of Venous Thromboembolic Disease. Value in Health 18(7): A339-A340, 2015

Hemorrhagic and thromboembolic complications versus intensity of treatment of venous thromboembolism with oral anticoagulants. Acta Medica Scandinavica 224(5): 425-430, 1988

Network Meta-Analysis of Oral Anticoagulants for Primary Prevention, Treatment and Secondary Prevention of Venous Thromboembolic Disease, and for Prevention of Stroke in Atrial Fibrillation. Value in Health 18(7): A374-A374, 2015

Thrombotic and bleeding outcomes following perioperative interruption of direct oral anticoagulants in patients with venous thromboembolic disease. Journal of Thrombosis and Haemostasis 15(5): 925-930, 2017

An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. Journal of the American Heart Association 2(5): E000136-E000136, 2014

Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: an analysis of the implications for perioperative management. Annals of Cardiac Anaesthesia 18(4): 517-527, 2016

Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment 21(9): 1-386, 2018

Impact of an education program on patient behaviour favoring prevention of drug-related adverse events: a pilot study in patients receiving oral anticoagulants for thromboembolic venous disease. Journal des Maladies Vasculaires 29(3): 152-158, 2004

New anticoagulants for venous thromboembolic disease. Idrugs 7(1): 50-57, 2004